Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. [electronic resource]
Producer: 20140408Description: 152-65 p. digitalISSN:- 1878-3686
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Blotting, Western
- Carcinoma, Basal Cell -- drug therapy
- Carcinoma, Squamous Cell -- drug therapy
- Cell Differentiation
- Cell Proliferation
- Cisplatin -- administration & dosage
- Clinical Trials, Phase II as Topic
- Cohort Studies
- Doxorubicin -- administration & dosage
- Drug Resistance, Neoplasm -- genetics
- Female
- Gene Expression Profiling
- Humans
- Male
- Methotrexate -- administration & dosage
- MicroRNAs -- genetics
- Muscle Neoplasms -- classification
- Mutation -- genetics
- Neoadjuvant Therapy
- Neoplasm Invasiveness
- Neoplasm Staging
- PPAR gamma -- genetics
- Prognosis
- RNA, Messenger -- genetics
- Real-Time Polymerase Chain Reaction
- Receptor, Fibroblast Growth Factor, Type 3 -- genetics
- Receptors, Estrogen -- genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Suppressor Protein p53 -- genetics
- Urinary Bladder Neoplasms -- classification
- Vinblastine -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.